SVF
Level A· Stronger Clinical EvidenceSystematic Review

A Comparison of the Properties of Mesenchymal Stem Cells Derived from Different Synovial Sources: A Systematic Review.

Ahmad M., Kapoor JS., Wilegoda WADCS., Liu M., Khan W.

Systematic Review on Osteoarthritis, Cartilage Damage, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Int J Mol Sci (2026)
Country
Switzerland
Reported sample size
—
PMID
42353294
DOI
10.3390/ijms27125582

Abstract (original English)

Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation into different cellular lineages, including adipocytes, chondrocytes, and osteocytes. This makes them strong candidates for repairing degenerative joint conditions such as osteoarthritis, in which native cartilage lacks repair capacity. The synovium is an attractive MSC source, with synovial MSCs demonstrating superior chondrogenic and proliferative potential compared to those from bone marrow or adipose tissue. The synovial joint is a heterogeneous environment, and MSCs can be isolated from the membrane, fluid, different histological subtypes of fibrous and adipose synovium, and different anatomical regions of synovium. This systematic review assesses whether MSCs from different synovial sources possess distinct properties. 2312 papers were identified, of which 10 met the inclusion and exclusion criteria and were included in the final review. Significant differences were identified in proliferation characteristics, immunophenotype and differentiation potential. Proximity to vasculature appeared to correlate with proliferation and differentiation potential, and MSCs from the synovial membrane may have superior proliferative characteristics compared to those from synovial fluid. More work is required to fully characterise these differences and understand their underlying molecular bases, but these find

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Mesenchymal Stem CellsHumansSynovial MembraneCell DifferentiationSynovial FluidAnimalsChondrogenesisCell Proliferation
OsteoarthritisCartilage Damage
View on PubMedDOI

Related research